
Ionis and Sobi agree on olezarsen commercialisation
Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS) and severely elevated triglycerides. Sobi’s rights cover nations …